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Abstract  1 
 Nanoparticles such as liposomes have been applied for the treatment of various diseases 2 
such as cancer and inflammatory diseases by utilizing the enhanced permeability and retention effect. 3 
However, their entry into inflammation sites is still limited since passive delivery of nanoparticles is 4 
often hampered by the presence of endothelial barriers. As leukocytes can pass through the inflamed 5 
endothelium via utilizing membrane protein functions, we hypothesized that incorporating leukocyte 6 
membrane proteins onto liposomal membranes may impart leukocyte-mimicking functions to 7 
liposomes, allowing for their adherence to and active passage through the inflamed endothelium. 8 
Herein, we developed leukocyte-mimetic liposomes (LM-Lipo) by leukocyte membrane protein 9 
transfer and evaluated their function in vitro. Transfer of membrane proteins from human leukemia 10 
cells onto liposomal membranes allowed for significant association of the liposomes with inflamed 11 
human endothelial cells, and subsequent passage through inflamed endothelial cell layer. The 12 
confocal images showed that LM-Lipo significantly induced vascular endothelial-cadherin 13 
displacement. These results indicate that LM-Lipo adhered to and regulated intercellular junctions of 14 
inflamed endothelial cell layer, resulting in passage through the layer, by mimicking the function of 15 
leukocytes. Furthermore, it is suggested that liposomes possessing leukocyte-like functions could be 16 
useful for drug delivery to inflammation sites by overcoming endothelial barriers. 17 
 18 
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1. Introduction 1 
 To develop new therapies for the treatment of a variety of diseases, delivery of drugs using 2 
nanoparticle drug delivery system (DDS), such as liposomes, has been broadly employed (Oku, 3 
2017). For example, application of liposomes for cancer therapy is a well-known approach (Miao et 4 
al., 2015), and our previous studies demonstrated the applicability of liposomes for the treatment of 5 
cerebral ischemia/reperfusion injury, one of the inflammatory diseases (Fukuta et al., 2017; Ishii et 6 
al., 2012). The therapeutic approaches for cancer and certain inflammatory diseases are based on 7 
selective accumulation of liposomes in the diseased sites by passive extravasation through leaky 8 
blood vessels by the enhanced permeability and retention effect (Maeda et al., 2000). Also, to 9 
increase the accumulation amount and therapeutic efficacy of nanoparticles in the diseased sites, 10 
their modification with specific targeting ligands (e.g., antibodies and peptides) has been broadly 11 
reported (Byrne et al., 2008; Nishikawa et al., 2012; Zhao et al., 2016). However, nanoparticle entry 12 
into the sites of inflammation-related diseases is still limited since delivery of such nanoparticles to 13 
the diseased area is dependent on passive process and is often hampered by the presence of 14 
biological barriers including endothelial cells (Anselmo et al., 2015; Blanco et al., 2015). Thus, to 15 
achieve more secure drug delivery into the inflammation sites, functionalization of nanoparticles to 16 
allow for their active passage through the inflamed endothelial barriers is needed. 17 
 In recent years, focus has been on application of circulatory cells (e.g., red blood cells, 18 
leukocytes and platelets) as functional elements of drug carriers for the development of novel 19 
nanoparticles that utilize the properties of those cells, namely, biomimetic DDS (Anselmo and 20 
Mitragotri, 2014; Luk and Zhang, 2015). In particular, leukocytes are known to bind to inflamed 21 
endothelial cells via certain adhesion molecules, including intercellular adhesion molecule-1 22 
(ICAM-1), and migrate to the site of inflammation, which leads to further pathological progression 23 
of inflammatory diseases via release of inflammatory mediators (Iadecola and Anrather, 2011; 24 
Vestweber, 2015). Indeed, it was reported that synthetic nanoparticles decorated with leukocyte 25 




area (Kang et al., 2017; Parodi et al., 2013). Based on these findings, we hypothesized that 1 
incorporation of leukocyte membrane proteins onto liposomal membranes may allow them to obtain 2 
leukocyte-mimicking functions, and facilitate the ability of the resultant liposomes to adhere to and 3 
actively pass through the inflamed endothelium around the diseased site, similar to leukocytes. 4 
 As mentioned above, imparting biomimetic properties to nanoparticles is expected to be an 5 
attractive strategy for targeted delivery to inflammation sites beyond the inflamed endothelial barrier. 6 
However, for bringing about biomimetic properties to nanoparticles, complicated processes, loss of 7 
protein activities, and difficulty in controlling physical properties (e.g., size and homogeneity) have 8 
been mentioned to be improved (Millan et al., 2004; Molinaro et al., 2016). It was previously 9 
reported that various membrane proteins can be spontaneously transferred to liposomal membranes 10 
without the need for solubilization and protein reconstitution steps using detergents, organic solvents, 11 
sonication, etc., a phenomenon known as intermembrane protein transfer (Huestis and Newton, 1986; 12 
Newton and Huestis, 1988). Since the transferred proteins retain their native activity and orientation 13 
in the lipid bilayer, intermembrane protein transfer was employed as a protein reconstitution method 14 
to provide functions to liposomes as well as other materials (Kogure et al., 1997b; Okumura et al., 15 
1994). For example, a cancer vaccine was prepared by reconstitution of tumor antigens onto 16 
liposomes via intermembrane protein transfer, and was subsequently demonstrated to result in 17 
successful tumor regression in tumor model mice (Shibata et al., 1991). We previously also reported 18 
that transfer of an influenza virus fusion protein, namely hemagglutinin, to erythrocyte ghosts 19 
enabled the ghosts to fuse with cells, resulting in delivery of entrapped proteins into the cells 20 
(Kogure et al., 2000). Hence, this protein reconstitution method is considered a promising approach 21 
for easily imparting leukocyte-mimicking properties onto liposomes. 22 
 As one of the mechanisms of leukocyte passage through the inflamed endothelium 23 
following binding to adhesion molecules, interaction of membrane proteins, namely lymphocyte 24 
function-associated antigen-1 (LFA-1; CD11a) and macrophage antigen-1 (Mac-1; CD11b), with 25 




inflamed endothelium via binding of both CD11a and CD11b to ICAM-1, activation of the ICAM-1 1 
signaling pathway is induced, leading to an increase in permeability of the endothelial cells and 2 
leukocyte infiltration into the inflammatory sites (Etienne-Manneville et al., 2000; Palomba et al., 3 
2016). Therefore, transfer of leukocyte membrane proteins including both CD11a and CD11b onto 4 
liposomal membranes is considered to enable the liposomes to exhibit the ability to not only adhere 5 
to but also pass through the inflamed endothelium via interactions with ICAM-1. To this end, we 6 
used a human promyelocytic leukemia cell line, namely HL-60 cell, as a donor of leukocyte 7 
membrane proteins in this study, since HL-60 cells constitutively express CD11a. Additionally, 8 
CD11b expression can be induced by differentiation into neutrophil-like cells by the treatment with 9 
all-trans retinoic acid (ATRA) (Trayner et al., 1998). For evaluating the function of liposomes, we 10 
used tumor necrosis factor-α (TNF-α)-treated human umbilical vein endothelial cells (HUVECs) as a 11 
model of inflamed endothelium since treatment with TNF-α was reported to induce ICAM-1 12 
expression in HUVECs (Ramana et al., 2004). 13 
 In the present study, we aimed to develop liposomes possessing leukocyte-mimicking 14 
functions, namely leukocyte-mimetic liposomes (LM-Lipo), via transfer of membrane proteins from 15 
HL-60 cells. Then, by using TNF-α-treated HUVECs as a model of inflamed endothelium, we 16 
investigated the ability of LM-Lipo to adhere to and actively pass through inflamed endothelial cell 17 





2. Material and Methods 1 
 2 
2.1. Cell cultures 3 
 The human promyelocytic leukemia cell line, HL-60, and human umbilical vein endothelial 4 
cells (HUVECs) were purchased from DS Pharma Biomedical Co., Ltd (Osaka, Japan) and 5 
PromoCell GmbH (Heidelberg, Germany), respectively. HL-60 cells were cultured in RPMI-1640 6 
medium (Nacalai tesque, Kyoto, Japan) supplemented with 10% fetal bovine serum, 100 U/mL 7 
penicillin (Gibco, MA, USA), and 100 μg/mL streptomycin (Gibco). HUVECs were cultured in 8 
endothelial growth medium (EGM-2, PromoCell GmbH) composed of endothelial basal medium 9 
(EBM-2, PromoCell GmbH), 30 μg/mL gentamicin sulfate (30 μg/mL)/amphotericin B (15 ng/mL) 10 
(GA-1000; Lonza, Tokyo, Japan) and endothelial cell growth medium-2 supplement pack 11 
(PromoCell GmbH). HUVECs used in the present study were between passage 3 and 6. The cells 12 
were cultured at 37ºC in a 5% CO2 incubator. 13 
  14 
2.2. Differentiation of HL-60 cells 15 
 HL-60 cells (1.0 x 106 cells/3 mL) seeded onto a 60-mm dish were incubated in RPMI-1640 16 
medium containing 1 μM all-trans retinoic acid (ATRA; Wako Pure Chemical, Osaka, Japan) 17 
dissolved in dimethyl sulfoxide (DMSO; Wako Pure Chemical). The final concentration of DMSO in 18 
the media was 0.1%. For the non-differentiated group, cells were incubated with 0.1% DMSO. After 19 
incubation for 0, 24, 48, 72, 96, and 120 h, the cells were harvested and washed with 20 
phosphate-buffered saline (PBS). The cells were then incubated with Fc receptor blocking solution 21 
(Human TruStain FcXTM; Biolegend, San Diego, CA, USA) at 4ºC for 10 min, followed by with 22 
Alexa Fluor 488-conjugated anti-human CD11b antibody (Biolegend) at 4ºC for 30 min. After 23 
washing the cells twice with PBS, the proportion of CD11b-positive cells, namely 24 
neutrophil-differentiated HL-60 cells, was measured by flow cytometry (Gallios; Beckman Coulter, 25 




2.3. Western blotting 1 
 Anti-CD11a rabbit monoclonal antibody (ab52895; Abcam, Cambridge, UK), anti-CD11b 2 
rabbit monoclonal antibody (ab133357; Abcam), anti-β-actin mouse monoclonal antibody (sc-47778; 3 
Santa Cruz Biotechnology, CA, USA), horse-radish peroxidase (HRP)-conjugated anti-rabbit IgG 4 
polyclonal antibody (A24531; Thermo Fisher Scientific, Waltham, MA,USA), and HRP-conjugated 5 
anti-mouse IgG rabbit polyclonal antibody (ab97046; Abcam) were purchased from the sources 6 
indicated. To examine the expression of CD11a and CD11b in HL-60 cells, the media of the cells 7 
cultured in the presence of 1 μM ATRA or 0.1% DMSO for 96 h were removed following 8 
centrifugation at 1,000 g for 5 min at 4ºC. The cells were washed with PBS, centrifuged, and the 9 
supernatant was subsequently removed. This cycle was repeated three times. The cells were then 10 
lysed with lysis buffer comprised of 1% Triton-X100, 10 mM Tris (pH 7.5), 50 μg/mL aprotinin, 200 11 
μM leupeptin, 2 mM phenylmethylsulfonyl fluoride, and 100 μM pepstatin A, followed by 12 
determination of protein concentration using a bicinchoninic acid (BCA) Protein Assay Reagent Kit 13 
(Pierce Biotechnology, Rockford, IL, USA). The resultant samples (10 μg protein) were subjected to 14 
10% SDS-PAGE, and the proteins were electrophoretically transferred to a polyvinylidene difluoride 15 
(PVDF) membrane (Bio-Rad, Hercules, CA, USA). The PVDF membrane was incubated with 3% 16 
bovine serum albumin (BSA) dissolved in Tris-HCl-buffered saline containing 0.1% Tween20 (pH 17 
7.4) for 1 h at 37ºC, followed by incubation with anti-CD11a at a dilution of 1:5000, anti-CD11b 18 
antibody (1:1000) or anti-β-actin antibody (1:20000) for 24 h at 4ºC, respectively. The PVDF 19 
membrane was then incubated with a secondary antibody at a dilution of 1: 2000 for rabbit IgG or 20 
1:50000 for mouse IgG for 1 h at 37ºC. Each protein was detected using a LAS-4000 mini system 21 
(Fuji Film, Tokyo, Japan) after incubation with a chemiluminescent substrate reagent (ECL prime; 22 
GE Healthcare, Little Chalfont, UK). 23 
 24 
2.4. Preparation of liposomes 25 




Sigma-Aldrich (Tokyo, Japan). Dioleoylphosphatidylethanolamine (DOPE) and 1 
dimyristoylphosphatidylcholine (DMPC) were purchased from NOF Corporation (Tokyo, Japan). 2 
Liposomes composed of EPC/DCP (7/3 molar ratio), EPC/DCP/DOPE (3.5/3/3.5 molar ratio), 3 
DMPC/DCP (7/3 molar ratio), and DMPC/DCP/DOPE (3.5/3/3.5 molar ratio) were prepared by the 4 
thin-film method. The above lipids dissolved in chloroform were added to test tubes and dried using 5 
nitrogen gas. To prepare fluorescence-labeled liposomes, 1, 6 
1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine perchlorate (DiIC18; Thermo Fisher Scientific, 7 
Waltham, MA, USA) dissolved in chloroform was added to the initial lipid solution at a 8 
concentration of 1 mol% of total lipid. The lipid film was hydrated with 0.3 M sucrose phosphate 9 
buffer (pH 7.4), and the liposomal suspensions were freeze-thawed for three cycles using dry-ice 10 
ethanol. The size of liposomes was then adjusted by extrusion through polycarbonate membrane 11 
filters with 100-nm pores (Nuclepore, Cambridge, MA, USA). The particle size and ζ-potential of the 12 
liposomes were measured with a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK). 13 
 14 
2.5. Intermembrane protein transfer 15 
 After culturing HL-60 cells in the presence of 1 μM ATRA or 0.1% DMSO for 96 h, the 16 
media were removed following centrifugation at 1,000 g for 5 min at 4ºC. The cells were washed 17 
with PBS and centrifuged, followed by removal of the supernatant. This cycle was repeated three 18 
times. Thereafter, the liposomal suspensions (1 mM as total lipids, 1 mL) were added and incubated 19 
with the cells (5 x 106 cells/1 mL of 1 mM liposomes) in a 35-mm dish for 90 min at 37ºC with 20 
shaking. As a control, 0.3 M sucrose phosphate buffer was also incubated with the cells. The 21 
incubated liposomes and 0.3 M sucrose phosphate buffer were harvested, centrifuged at 2,000 g for 1 22 
min, and the supernatants were recovered and centrifuged to remove the cells. This cycle was 23 






2.6. Observation of protein transfer onto liposomes 1 
 To prepare the liposome samples for BCA assay and SDS-PAGE, 1 mL of the recovered 2 
liposomes (1 mM) following intermembrane transfer were ultracentrifuged at 112,500 g for 60 min at 3 
4ºC (Optima L-90K; Beckman Coulter, Tokyo, Japan). The pellets of the liposomes were then 4 
resuspended in 100 μL of 0.3 M sucrose phosphate buffer to yield a liposome concentration of 10 5 
mM. To prepare the control sample, the incubated and recovered 0.3 M sucrose phosphate buffer was 6 
also ultracentrifuged as described above. For determining protein concentration of the resultant 7 
liposomes, the liposomes were solubilized in 1% Triton-X100, and then protein concentration of 8 
each liposomal sample was measured by using a BCA Protein Assay Reagent Kit (Pierce 9 
Biotechnology, Rockford, IL, USA) according to the manufacturer’s instructions. In the case of 10 
SDS-PAGE, the resultant samples (0.2 μmol as lipid concentration for the liposome samples or 10 μg 11 
protein for the cellular samples) were exposed to 10% SDS-PAGE. The proteins were then 12 
electrophoretically transferred to a PVDF membrane following SDS-PAGE. The PVDF membrane 13 
was then incubated with 3% BSA in Tris-buffered saline containing 0.1% Tween 20, each primary 14 
antibody, and secondary antibody, as described above. Finally, the proteins were incubated with ECL 15 
prime, and then detected with a LAS-4000 mini system. Quantification of signal intensities of each 16 
band in the images of Western blotting was performed by using an image-analysis system (ImageJ; 17 
National Institutes of Health, Bethesda, MD, USA). To calculate transfer efficiency of CD11a and 18 
CD11b onto liposomes, proportions of CD11a and CD11b in HL-60 cells were determined by silver 19 
staining (Silver Stain 2 Kit Wako, Wako Pure Chemical) following SDS-PAGE. 20 
 21 
2.7. Evaluation of liposome association with HUVECs 22 
 HUVECs were seeded onto a 35-mm glass bottom dish at a density of 1 x 105 cells/dish and 23 
incubated overnight. The cells were then treated with TNF-α (10 ng/mL in EGM-2) for 16 h. DiIC18 24 
(DiI)-labeled liposomes composed of EPC/DCP/DOPE (3.5/3/3.5 molar ratio) or DMPC/DCP/DOPE 25 




described above (see Intermembrane protein transfer). Liposomes mixed in EBM-2 at a 1 
concentration at 0.5 mM (as total lipids) were added onto TNF-α-treated HUVECs for 3 h at 37ºC. 2 
After removing the liposomes and washing twice with PBS, the cells were fixed with 4% 3 
paraformaldehyde (PFA) for 1 h at 37ºC. The cells were then washed with PBS three times, and then 4 
incubated with PBS containing 0.1% Triton X100 for 15 min at 37ºC, followed by incubation with 1 5 
μg/mL 4’, 6-diamidino-2-phenylindole (DAPI; Thermo Fisher Scientific) in PBS for 15 min at 37ºC. 6 
After washing with PBS, the fluorescence was observed using a fluorescence microscope (Axio 7 
Vert.A1, Carl Zeiss, Jena, Germany).  8 
 To quantify the amount of the liposomes associated with HUVECs, the cells were seeded 9 
onto 24-well plate at a density of 5 x 104 cells/well, and treated with TNF-α as mentioned above. 10 
Following treatment with each liposomal sample for 3 h, the cells were washed with PBS and lysed 11 
with 1% n-octyl-β-D-glucoside (Dojindo, Kumamoto, Japan). The fluorescence intensity of DiI was 12 
determined using a Tecan Infinite M200 microplate reader (Salzburg, Männedorf, Switzerland). 13 
Thereafter, the total protein content was measured using a BCA Protein Assay Reagent Kit. 14 
 15 
2.8. Transwell permeability assay 16 
 HUVECs were seeded onto a 6.5-mm Transwell plate with 8-μm pore polyester membrane 17 
inserts (Costar, Corning, Kennebunk, ME, USA) at a density of 2 x 105 cells/insert. The inserts were 18 
pre-incubated with 0.1% gelatin in PBS for 1 h at 37ºC, followed by EGM-2 overnight before 19 
seeding. At 48 h after seeding, the media on both the upper and bottom compartments were removed, 20 
and EGM-2 containing TNF-α (10 ng/mL) was then added to both compartments. At 16 h after 21 
incubation with TNF-α, the cells were treated with the liposomes (50 nmol as lipid dose/insert) 22 
incubated with non-differentiated or differentiated HL-60 cells, which liposomes were mixed in 23 
EBM-2 at a concentration of 0.5 mM. At 3 h after incubation, the media in the bottom comportment 24 
was collected and the DiI fluorescence was measured using a Tecan Infinite M200 microplate reader 25 




2.9. Actin staining and immunostaining 1 
 HUVECs were seeded onto a 35-mm glass bottom dish coated with 0.1% gelatin and 2 
incubated overnight. The cells were treated with TNF-α and liposomes as described above (see 3 
Evaluation of liposome association with HUVECs). For filamentous actin (F-actin) staining, cells 4 
were treated with liposomes for 3 h at 37ºC, washed with PBS, and subsequently fixed in 4% PFA 5 
for 10 min at 37ºC following liposomal incubation. After washing twice with PBS, HUVECs were 6 
permeabilized with PBS containing 0.1% Triton-X100 for 5 min at 37ºC. The cells were then 7 
incubated in PBS containing 1% BSA for 20 min at 37ºC, followed by incubation with Alexa Fluor 8 
488 phalloidin in PBS (1:40; Thermo Fisher Scientific) for 20 min at room temperature. After 9 
washing with PBS, the cells were stained with DAPI, and the fluorescence was observed by confocal 10 
laser scanning microscopy (LSM700, Carl Zeiss). 11 
 For immunostaining of vascular endothelial-cadherin (VE-cadherin), cells were washed with 12 
PBS, fixed with 4% PFA for 20 min at 37ºC, and permeabilized in PBS containing 1% BSA and 13 
0.1% TritonX-100 for 20 min. The cells were then incubated with rabbit anti-VE-cadherin antibody 14 
(2.5 μg/mL; ab33168; Abcam) for 1 h at 37ºC, followed by washing with PBS containing 1% BSA 15 
and then incubation with Alexa Fluor 488-conjugated goat anti-rabbit IgG (1:200; ab150077; Abcam) 16 
for 1 h at 37ºC. After washing, the nuclei were stained with 1 μg/mL DAPI solution for 15 min at 17 
37ºC. The fluorescence of the cells was monitored using a confocal laser scanning microscope. To 18 
evaluate level of VE-cadherin expression, the experiments were performed 5 times independently, 19 
and fluorescence intensities of VE-cadherin positive areas between cell borders were analyzed for 20 
total 40 or more images per each group of HUVECs using an image-analysis system ImageJ. 21 
 22 
2.10. Statistical analysis 23 
 Statistical differences were evaluated by one-way analysis of variance (ANOVA) with the 24 





3. Results 1 
 2 
3.1. Differentiation of HL-60 cells into neutrophil-like cells by ATRA 3 
 We firstly evaluated the differentiation of HL-60 cells into neutrophil-like cells by ATRA 4 
treatment for the preparation of donor cells to transfer the leukocyte membrane proteins CD11a and 5 
CD11b onto liposomal membranes. Flow cytometry results showed that cultivation of HL-60 cells in 6 
the presence of 1 μM ATRA significantly increased CD11b-positive cells in a time-dependent 7 
manner following initiation of ATRA treatment, whereas CD11b-positive cells did not increase in 8 
HL-60 cells cultured in the absence of ATRA (Figs. 1A and B). Since the percentage of 9 
CD11b-positive cells approached nearly 80% at 96 h after ATRA treatment and remained unchanged 10 
at 120 h (Fig. 1B), the differentiation of HL-60 cells into neutrophil-like cells was certainly achieved 11 
by the ATRA treatment for 96 h. Western blotting showed that HL-60 cells treated with ATRA for 96 12 
h expressed both CD11a and CD11b, whereas those not treated with ATRA did not express CD11b 13 
(Fig. 1C). Based on these results, we decided to use those cells treated with ATRA for 96 h as 14 
neutrophil-differentiated cells, i.e., as donor cells of leukocyte membrane proteins, in subsequent 15 
experiments. On the other hand, the expression level of CD11a was significantly reduced to 16 
approximately 60% by the treatment with ATRA (Fig. 1D and Supplementary Fig. 1). 17 
 18 
3.2. Intermembrane transfer of leukocyte membrane proteins from HL-60 cells onto liposomes 19 
 Using both differentiated and non-differentiated HL-60 cells, we examined the 20 
intermembrane protein transfer of membrane proteins onto liposomal membranes. Since the protein 21 
transfer was previously reported to be facilitated by increasing membrane fluidity of recipient 22 
liposomes (Waters et al., 1996), we prepared liposomes composed of EPC (containing unsaturated 23 
phospholipids) and liposomes composed of the saturated phospholipid DMPC to confirm the 24 
influence of membrane fluidity on protein transfer efficiency. Moreover, as previous studies reported 25 




via incorporation of the amphiphilic compound DCP into the liposomes (Kogure et al., 1997a; 1 
Kogure et al., 1999), we also prepared liposomes containing DCP. In addition, we incorporated the 2 
fusogenic phospholipid DOPE, because intermembrane protein transfer is induced by partial fusion 3 
between cellular membranes and liposomal membranes (Huestis and Newton, 1986; Newton and 4 
Huestis, 1988). Particle size, polydispersity index, and ζ-potential of liposomes used in the present 5 
study are shown in Table 1. The particle size and ζ-potential of each of the prepared liposomes was 6 
approximately 100-150 nm and -10 mV, respectively. To determine total protein concentration in the 7 
recovered liposome suspensions, BCA assay was performed for each liposome suspension incubated 8 
with differentiated or non-differentiated HL-60 cells. The results showed that the protein 9 
concentration tended to increase by incorporating DOPE in both EPC- and DMPC-based liposomes, 10 
and the concentrations were higher in the case of liposomal suspension been incubated with 11 
differentiated HL-60 cells (ATRA (+)) than that with non-differentiated cells (ATRA (-)) (Fig. 2). On 12 
the other hand, the particle sizes of the liposomes increased and the ζ-potentials became more 13 
negatively charged after incubation with HL-60 cells (Table 1).  14 
 15 
Table 1. Physicochemical properties of liposomes before and after intermembrane protein transfer. 16 
 Particle size (d. nm) Polydispersity index ζ-Potential (mV) 
Before After Before After Before After 
EPC/DCP 
-Lipo 
113.9 12.2 126.0 18.0 0.26 0.11 0.24 0.03 -9.7 1.0 -13.7 2.5 
EPC/DCP/ 
DOPE-Lipo 
109.6 12.2 150.7 14.4 0.21 0.09 0.35 0.08 -11.3 3.6 -16.0 1.8 
DMPC/DCP 
-Lipo 
145.0 28.0 185.0 61.1 0.37 0.11 0.49 0.13 -9.8 1.4 -13.3 1.4 
DMPC/DCP/ 
DOPE-Lipo 






Next, transfer of CD11a and CD11b onto liposomes was evaluated by Western blotting. The 1 
results of Western blotting showed that the presence of CD11a was observed in liposomal samples 2 
incubated with HL-60 cells (Fig. 3A). Importantly, CD11b was only observed in those liposomes 3 
incubated with ATRA-treated neutrophil-differentiated HL-60 cells (Fig. 3B). Considering the 4 
differences in liposome composition, in the groups of liposomes containing DOPE, both CD11a and 5 
CD11b were more clearly detected compared with the groups of liposomes containing only DCP 6 
(EPC/DCP-Lipo and DMPC/DCP-Lipo). However, neither CD11a nor CD11b was observed upon 7 
incubation of the cells with 0.3 M sucrose phosphate buffer. Quantitative data of Western blotting 8 
indicated that transfer amount of CD11a was significantly higher in the group of 9 
EPC/DCP/DOPE-Lipo compared with EPC/DCP-Lipo and DMPC/DCP-Lipo, and also higher than 10 
that of DMPC/DCP/DOPE-Lipo (Figs. 3C and D). In the case of CD11b, its transfer amount tended 11 
to be higher in the groups of liposomes containing DOPE (Fig. 3E). Since proportions of CD11a and 12 
CD11b in HL-60 cells were indicated to be approximately 1 % from silver staining following 13 
SDS-PAGE (data not shown), transfer efficiency of HL-60 cell membrane proteins, and that of 14 
CD11a and CD11b onto liposomes was estimated as shown in Supplementary Table 1. The data also 15 
indicated that incorporation of DOPE into liposomes could increase transfer efficiency of both 16 
CD11a and CD11b. Based on these results, it was indicated that transfer of leukocyte membrane 17 
proteins CD11a and CD11b onto liposomes was achieved by intermembrane protein transfer. The 18 
resultant liposomes possessing leukocyte membrane proteins were designated as “leukocyte-mimetic 19 
liposomes (LM-Lipo)”. EPC/DCP/DOPE-Lipo (EPC/DO-Lipo) and DMPC/DCP/DOPE-Lipo 20 
(DMPC/DO-Lipo) were used in subsequent experiments. 21 
 22 
3.3. Association of leukocyte-mimetic liposomes (LM-Lipo) with TNF-α-treated HUVECs 23 
 Next, association of LM-Lipo with inflamed endothelial cells was investigated using 24 
TNF-α-treated HUVECs as an in vitro model, since it has been reported that treatment with TNF-α 25 




ICAM-1 was time-dependently and significantly increased at 16 h after TNF-α treatment, at which 1 
point ICAM-1 expression became the highest under the experimental conditions (Supplementary Fig. 2 
2). By using fluorescence (DiI)-labeled liposomes, we evaluated the association of LM-Lipo with 3 
TNF-α-treated HUVECs using a fluorescence microscope. The results showed that the DiI 4 
fluorescence of HUVECs treated with leukocyte-mimetic EPC/DO-Lipo (LM-EPC/DO-Lipo) or 5 
DMPC/DO-Lipo (LM-DMPC/DO-Lipo) was stronger than plain liposomes regardless of whether 6 
HL-60 cells had been differentiated (ATRA (+)) or not (ATRA (-)) (Figs. 4A, B, D, and E). 7 
Importantly, higher fluorescence intensities were observed for TNF-α-treated HUVECs in both the 8 
LM-EPC/DO-Lipo and LM-DMPC/DO-Lipo groups compared with untreated HUVECs. The 9 
confocal images also showed that DiI fluorescences in TNF-α-treated HUVECs incubated with 10 
LM-EPC/DO-Lipo (ATRA (-)) and ATRA (+)) or LM-DMPC/DO-Lipo (ATRA (+)) were higher than 11 
plain liposomes (Supplementary Fig. 3). Also, some areas with higher fluorescence than other areas 12 
were observed, which were considered to be resulted from the liposomes localized in endosomes. 13 
The DiI fluorescence was also determined by lysing the cells, and the results indicated that the 14 
fluorescence intensity of the cells treated with LM-Lipo was significantly higher than that with plain 15 
liposomes in TNF-α-treated HUVECs (Figs. 4C and F). Moreover, LM-EPC/DO-Lipo incubated 16 
with non-differentiated (LM-EPC/DO-Lipo ATRA (-)) or differentiated HL-60 cells 17 
(LM-EPC/DO-Lipo ATRA (+)) and LM-DMPC/DO-Lipo (ATRA (+)) had significantly higher 18 
affinity to TNF-α-treated HUVECs compared with untreated ones, suggesting that those negatively 19 
charged liposomes attained leukocyte-mimetic properties to facilitate their adherence to inflamed 20 
endothelial cells. Because LM-DMPC/DO-Lipo showed lower affinity to TNF-α-treated HUVECs 21 
than LM-EPC/DO-Lipo, LM-EPC/DO-Lipo were used in subsequent experiments.  22 
 23 
3.4. Passage of leukocyte-mimetic liposomes through TNF-α-treated HUVECs 24 
 Next, the ability of LM-Lipo to pass through inflamed endothelial cell layer was evaluated 25 




the upper compartments of the TNF-α-treated HUVECs cultured on the inserts, and the DiI 1 
fluorescence of the media in the bottom compartments was measured 3 h after liposomal treatment. 2 
The results showed that there was almost no difference between the groups of cells treated with 3 
EPC/DO-Lipo or LM-EPC/DO-Lipo (ATRA (-)), whereas the fluorescence intensity in the bottom 4 
compartment was higher in the LM-EPC/DO-Lipo (ATRA (+))-treated group compared with that in 5 
the EPC/DO-Lipo-treated group (Fig. 5). These results suggest that LM-EPC/DO-Lipo (ATRA (+)) 6 
not only adhered to but also passed through inflamed endothelial cell layer. 7 
 8 
3.5. Influence of leukocyte-mimetic liposomes on cytoskeleton and intercellular adhesion 9 
junctions of inflamed endothelial cells 10 
 To analyze the mechanism of passage of LM-EPC/DO-Lipo (ATRA (+)) through the 11 
TNF-α-treated HUVEC layer, we investigated the influence of liposomal treatment on the 12 
cytoskeleton and intercellular adhesion junctions of inflamed endothelial cells. Confocal images of 13 
F-actin staining showed that the treatment with LM-EPC/DO-Lipo, especially LM-EPC/DO-Lipo 14 
(ATRA (+)), induced intracellular morphological changes of F-actin in TNF-α-treated HUVECs 15 
compared with non-treated HUVECs (Figs. 6A-D). As shown in Figure 6D, in the HUVECs treated 16 
with LM-EPC/DO-Lipo (ATRA (+)), the state of F-actin was changed and became sharp-shaped 17 
structures, and intracellular fluorescence derived from F-actin (Alexa Fluor 488 phalloidin) 18 
decreased compared with control (TNF-α (-)) and EPC/DO-Lipo groups. 19 
 We then evaluated the effect of treatment with LM-Lipo on the state of the intercellular 20 
adhesion protein, VE-cadherin, in TNF-α-treated HUVECs. Confocal images showed that expression 21 
of VE-cadherin and cell borders were clearly observed in normal HUVECs (Fig. 7A). Although the 22 
apparent formation of intercellular junctions was observed in TNF-α-treated cells treated with plain 23 
EPC/DO-Lipo (Fig. 7B), the fluorescence signals derived from VE-cadherin expression was 24 
decreased in the LM-EPC/DO-Lipo (ATRA (-))-treated cells, and the intercellular adhesions were 25 




markedly perturbed VE-cadherin expression and the formation of intercellular junctions compared to 1 
the other groups (Fig. 7D). The quantification data also indicated that the level of VE-cadherin 2 
expression in TNF-α-treated HUVECs incubated with LM-EPC/DO-Lipo (ATRA (+)) was 3 
significantly lower than the HUVECs incubated with plain EPC/DO-Lipo, and tended to be 4 
decreased compared with the cells treated with LM-EPC/DO-Lipo (ATRA (-)) (Fig. 7E). On the 5 
other hand, the expression of VE-cadherin was almost not changed by the treatment with 6 
EPC/DO-Lipo in the absence of TNF-α (Supplementary Figs. 5A and B). We also confirmed that 7 
HL-60 cells could induce morphological change of F-actin in TNF-α-treated HUVECs and the state 8 
of F-actin became sharp-shaped structures (Supplementary Fig. 4). In addition, the expression of 9 
VE-cadherin decreased in the TNF-α-treated HUVECs incubated with HL-60 cells, especially with 10 
ATRA-treated (differentiated) HL-60 cells, in comparison to HUVECs treated with TNF-α alone 11 
(Supplementary Figs. 5C and D), as reported previously in leukocytes (Isac et al., 2011; Vestweber, 12 
2012). These results suggest that the LM-EPC/DO-Lipo (ATRA (+)) regulates intercellular junctions 13 
of the TNF-α-treated HUVECs by exerting functions of both CD11a and CD11b derived from 14 





4. Discussion 1 
 Since accumulation of nanoparticles into the sites of tumor and inflammation is dependent 2 
on passive process, design of nanoparticles which can actively overcome the inflamed endothelium 3 
and accumulate in the diseased area is required (Anselmo et al., 2015; Blanco et al., 2015). 4 
Leukocytes are known to adhere to and pass through the inflamed endothelium via the interaction of 5 
their membrane proteins and adhesion molecules expressed on the endothelial cells 6 
(Etienne-Manneville et al., 2000; Vestweber, 2015). Thus, we hypothesized that incorporation of 7 
leukocyte membrane proteins onto liposomes could enable the liposomes to mimic the function of 8 
leukocytes, and thus allow for their active passage through the inflamed endothelium. Herein, we 9 
employed intermembrane protein transfer as a protein reconstitution method to impart nanoparticles 10 
with biomimetic properties, since this method is reported to be able to transfer cellular membrane 11 
proteins onto liposomal membranes with native orientation and activities (Huestis and Newton, 1986; 12 
Newton and Huestis, 1988). In the present study, we used liposomes containing the amphiphilic 13 
compound DCP because it was previously revealed that incorporation of DCP into liposomes induces 14 
phase separation of the liposomal membrane, resulting in increase in the efficiency of membrane 15 
protein transfer (Kogure et al., 1997a; Kogure et al., 1999). Similar to the previous studies, results 16 
shown in Fig. 3 confirmed the transfer of the membrane proteins of neutrophil-differentiated HL-60 17 
cells, CD11a and CD11b, onto liposomes containing DCP. Additionally, the results of Western 18 
blotting showed that the transfer was more clearly observed in the group of liposomes composed of 19 
EPC than liposomes composed of DMPC (Figs. 3A and B). These results are consistent with a 20 
previous report, which showed that protein transfer is facilitated by increasing the membrane fluidity 21 
of the liposomes (Waters et al., 1996). In particular, when the fusogenic unsaturated phospholipid 22 
DOPE was incorporated into liposomes, higher transfer efficiency was observed both in EPC- and 23 
DMPC-based liposomes (Figs. 2 and 3). In fact, the amounts of total proteins, CD11a, and CD11b in 24 
the liposome suspensions collected after incubation with the cells tended to be higher both in EPC- 25 




incorporation of DOPE into liposomes could increase the efficiency of intermembrane protein 1 
transfer. 2 
 As shown in Fig. 1D and supplementary Fig. 1, differentiation of HL-60 cells by ATRA 3 
treatment significantly reduced CD11a expression levels to approximately 60% of non-differentiated 4 
HL-60 cells, although CD11b expression was induced by ATRA treatment (Figs. 1A-C). On the other 5 
hand, the amount of CD11a transferred onto liposomes from ATRA-treated differentiated HL-60 cells 6 
were larger than or almost same as that from non-differentiated cells (Supplementary Table 1), 7 
despite the CD11a expression level in differentiated HL-60 cells been lower than that in 8 
non-differentiated cells. From these results, it is considered that transfer efficiency of cellular 9 
membrane proteins via intermembrane protein transfer would be changed by the state of donor cells. 10 
 Leukocytes are known to adhere to inflamed endothelium and infiltrate into the site of 11 
inflammation by utilizing the functions of their carbohydrate chains and membrane proteins. In 12 
particular, the membrane proteins CD11a and CD11b, which were shown to be expressed in 13 
ATRA-induced neutrophil-differentiated HL-60 in our present study (Fig. 1) as well as in previous 14 
reports (Gee et al., 2012), have been reported to interact with ICAM-1 (Diamond et al., 1991; van 15 
Buul et al., 2007). Thus, to evaluate the leukocyte-mimicking ability of LM-Lipo, we first examined 16 
the association of the liposomes with inflamed endothelial cells using TNF-α-treated HUVECs, 17 
which express ICAM-1 as shown in Supplementary Fig. 2. The results showed that LM-Lipo 18 
significantly associated with the TNF-α-treated HUVECs compared with plain liposomes (Fig. 4). In 19 
addition, the liposomes showed significantly higher affinity to TNF-α-treated HUVECs than to 20 
untreated HUVECs (Fig. 4). Since CD11a has been reported to be involved in leukocyte adhesion to 21 
inflamed endothelium, it is considered that liposomes incubated with non-differentiated HL-60 cells 22 
could also significantly associate with TNF-α-treated HUVECs. These results suggest that liposomes 23 
possessing leukocyte membrane proteins could attain leukocyte-mimetic functions and selectively 24 
adhere to inflamed endothelial cells via ICAM-1. Moreover, it was confirmed that the transferred 25 




the liposomal membranes. 1 
 In the present study, LM-EPC/DO-Lipo (ATRA (+)) demonstrated an ability to pass through 2 
TNF-α-treated HUVEC layer cultured onto a Transwell plate compared with plain EPC/DO-Lipo 3 
(Fig. 5). As one of the mechanisms of leukocyte extravasation across inflamed endothelium via 4 
binding to adhesion molecules, it has been demonstrated that interaction of CD11a and CD11b on 5 
leukocytes with ICAM-1 on endothelial cells induces activation of the ICAM-1 signaling pathway 6 
(Palomba et al., 2016). This activation leads to a subsequent increase in intracellular calcium 7 
concentration, protein kinase C-α activation, and phosphorylation of VE-cadherin, which results in 8 
displacement of VE-cadherin and formation of gaps between the inflamed endothelial cells 9 
(Sandoval et al., 2001; Turowski et al., 2008). It has also been reported that when leukocytes pass 10 
through inflamed endothelium via the paracellular route, actin depolymerization is induced in 11 
addition to displacement of intercellular junction proteins (Mamdouh et al., 2009). In fact, the 12 
displacement of VE-cadherin and decrease in its expression level, and change of actin cytoskeleton 13 
were seen in TNF-α-treated HUVECs incubated with LM-Lipo possessing both CD11a and CD11b 14 
(Figs. 6 and 7). Based on these results, it is suggested that interaction of both CD11a and CD11b on 15 
LM-Lipo with ICAM-1 resulted in activation of the ICAM-1 signaling pathway by exerting their 16 
functions. This signal activation subsequently induced displacement of VE-cadherin and increased 17 
the permeability between the cells, resulting in passage of LM-Lipo through the inflamed HUVEC 18 
layer.  19 
 Liposomes could attain leukocyte-mimicking abilities by reconstitution of leukocyte 20 
membrane proteins, especially CD11a and CD11b, via intermembrane protein transfer. Since the 21 
protein reconstitution method nonspecifically transfers membrane proteins onto liposomes, other 22 
proteins might interact with other endothelial adhesion molecules involved in leukocyte 23 
extravasation (Vestweber, 2015). However, it is possible that modification of the liposome surface 24 
with both CD11a and CD11b, or peptides containing ICAM-1 recognition domains that subsequently 25 




to inflamed endothelial cells and perturbation of intercellular junctions, leading to passage of the 1 
nanoparticles through endothelial cell layer into inflammation sites. Design of such nanoparticles 2 
should be both useful and interesting for future studies. 3 
 LM-EPC/DO-Lipo (ATRA (+)) developed in this study exhibited leukocyte-mimicking 4 
properties by regulating cellular junctions of inflamed endothelial cells and passing through the 5 
endothelial cell layer. Hence, LM-Lipo has the potential to be useful in applications for the treatment 6 
of inflammatory diseases, similar to leukocytes invading the inflammation sites. In previous reports, 7 
leukocyte-mimetic nanoparticles were prepared via complicated steps, i.e., collection and 8 
purification of cellular membrane fractions from cell lysates by density gradient centrifugation, 9 
followed by their modification onto nanoparticles by chemical conjugation or physical processes 10 
such as sonication and extrusion (Kang et al., 2017; Parodi et al., 2013). On the other hand, the 11 
intermembrane protein transfer employed in the present study has the advantage that cellular 12 
membrane proteins can be easily transferred with their native activity and orientation by only 13 
incubating the liposomes with the cells (Huestis and Newton, 1986; Shibata et al., 1991). Also, our 14 
present study demonstrated that it is possible to construct biomimetic DDS even by such a more 15 
simple method than conventional methods reported previously. In vivo applications using leukocytes 16 
derived from animal blood should be considered a necessary next step in demonstrating further 17 
utility of LM-Lipo. Since inflammation has been reported to be involved in the pathological 18 
progression of a number of diseases (Chu et al., 2015; Eltzschig and Eckle, 2011; Maeda et al., 2013), 19 
application of LM-Lipo could become a hopeful approach for developing treatments for such 20 





5. Conclusions 1 
 In summary, development of LM-Lipo could be achieved by intermembrane transfer of 2 
leukocyte membrane proteins onto liposomal membranes. LM-Lipo was able to associate with 3 
TNF-α-treated ICAM-1-expressing HUVECs and pass through the cell layer by exerting the 4 
functions of leukocyte membrane proteins. Moreover, the mechanism of passage is considered to be 5 
due to the displacement of VE-cadherin accompanying change of actin cytoskeleton by interaction of 6 
both CD11a and CD11b with ICAM-1. Hence, the present findings suggest that imparting 7 
leukocyte-mimetic properties onto liposomes represents a promising approach to overcome 8 
endothelial barriers by regulating intercellular junctions, and that LM-Lipo could be a useful DDS 9 
for developing a new therapy for the treatment of inflammatory diseases. 10 
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Figure legends 9 
 10 
Figure 1. Differentiation of HL-60 cells into neutrophil-like cells by treatment with ATRA. 11 
 (A) HL-60 cells (1.0 x 106 cells/60-mm dish) were treated with 1 μM ATRA for 0, 24, 48, 72, 12 
96, or 120 h to induce differentiation into neutrophil-like cells. In the non-differentiated group, the 13 
cells were cultured in the presence of 0.1% DMSO. Following incubation, the cells were collected 14 
and stained with Alexa Fluor 488-conjugated anti-CD11b antibody. Thereafter, flow cytometric 15 
analysis was performed to measure the CD11b-positive cells. The white and gray histograms indicate 16 
cells treated without and with ATRA, respectively. (B) The percentage of CD11b-positive 17 
(neutrophil-differentiated) cells was determined from the histogram data. The data show the mean ± 18 
S.D. (n=3). (C, D) Expression of CD11b (Mac-1; C) and CD11a (LFA-1; D) in ATRA-treated and 19 
non-ATRA-treated groups was determined by Western blotting after incubation for 96 h. The 20 
experiments of Western blotting were performed 3 times independently. 21 
 22 
Figure 2. Determination of protein concentration of the recovered liposome suspensions after 23 
incubation with HL-60 cells. 24 
 Liposomes consisted of each lipid composition were incubated for 90 min with HL-60 cells 25 




liposomes incubated with non-differentiated HL-60 cells (ATRA (-)) or differentiated HL-60 cells 1 
(ATRA (+)) were determined by BCA assay. The data show the mean ± S.D. (n=4). The experiments 2 
were conducted 4 times independently. 3 
 4 
Figure 3. Transfer of leukocyte membrane proteins onto liposomes via intermembrane protein 5 
transfer with HL-60 cells. 6 
 (A, B) Liposomes comprised of each lipid composition or 0.3 M sucrose phosphate buffer 7 
were incubated with non-differentiated (ATRA (-)) or neutrophil-differentiated (ATRA (+)) HL-60 8 
cells for 90 min. Each lane indicates a specific liposome (0.2 μmol as total lipid) or cell extract of 9 
differentiated HL-60 cells (10 μg protein) that was subjected to SDS-PAGE. Western blot analysis 10 
was then performed to confirm the transfer of CD11a (A) and CD11b (B) onto the liposomes. Per the 11 
product datasheet, the detected molecular weights of CD11a and CD11b are approximately 180 kDa 12 
and 170 kDa, respectively. The bands in the leftmost lane correspond to the Western Protein Standard 13 
(MagicMarkTM XP; Thermo Fisher Scientific). (C-E) The signal intensities of the bands of CD11a 14 
(C; ATRA (-), D; ATRA (+)) and CD11b (E) transferred onto liposomes were calculated by using an 15 
image-analysis system Image J. The relative signal intensities of each band to that of differentiated 16 
HL-60 cells are presented. The data show the mean ± S.D. (C and D; n=3, E; n=4). Statistical 17 
differences were analyzed by ANOVA with Tukey post-hoc test. Significant differences; * P<0.05, 18 
** P<0.01. The experiments were performed 3 for A, C, and D and 4 times for B and E. 19 
 20 
Figure 4. Association of leukocyte-mimetic liposomes with TNF-α-treated inflamed HUVECs. 21 
 (A, B, D, E) HUVECs (1 x 105 cells/35-mm dish) were treated with TNF-α (10 ng/mL in 22 
EGM) for 16 h at 37ºC to induce expression of ICAM-1, as shown in Supplementary Fig. 2. 23 
DiI-labeled EPC/DO-Lipo, DMPC/DO-Lipo, and LM-Lipo prepared by incubation with HL-60 cells 24 
(ATRA (-) or ATRA (+)) were added onto untreated (A and D) or TNF-α-treated HUVECs (B and E), 25 




counterstained with DAPI. Fluorescence images were obtained by fluorescence microscopy. DiI 1 
(liposome; red, upper column) and merged images (lower column) of DAPI (nuclei; blue), DiI, and 2 
phase contrast are shown. Scale bars = 100 μm. (C, F) HUVECs (5 x 104 cells/well onto 24-well 3 
plate) were incubated with EGM-2 containing TNF-α (10 ng/mL) for 16 h at 37ºC. TNF-α-treated 4 
and untreated HUVECs were then treated with the indicated DiI-labeled liposomes for 3 h at 37ºC. 5 
After lysis of the cells, the fluorescence intensity of DiI in the cells was measured. The relative 6 
fluorescence intensity of each group to that in control (C: EPC/DO-Lipo, F: DMPC/DO-Lipo) are 7 
presented. The data show the mean ± S.D. (n=4). Statistical differences were calculated by ANOVA 8 
with Tukey post-hoc test. Significant differences; * P<0.05, # P<0.05, ## P<0.01 vs. DMPC/DO-Lipo, 9 
### P<0.001 vs. EPC/DO-Lipo. These experiments were performed 4 times independently. 10 
 11 
Figure 5. Passage of leukocyte-mimetic liposomes through inflamed endothelial cell layer. 12 
 HUVECs seeded on a Transwell plate (2 x 105 cells/inserts) were cultured for 48 h at 37ºC, 13 
followed by incubation with TNF-α (10 ng/mL) for 16 h at 37ºC. Next, DiI-labeled EPC/DO-Lipo or 14 
LM-EPC/DO-Lipo (ATRA (-) or (+)) was added (50 nmol as lipid dose/insert, 100 μL of each 15 
liposome at a concentration of 0.5 mM diluted with EBM-2) onto the upper compartment of the 16 
Transwell plate and incubated for 3 h at 37ºC. Thereafter, the fluorescence intensity of DiI in the 17 
media of the bottom compartment was measured. The relative fluorescence intensity of each group to 18 
that in control (EPC/DO-Lipo) are presented. The data show the mean ± S.D. (n = 20). Statistical 19 
differences were calculated by ANOVA with Tukey post-hoc test. Significant difference; * P<0.05 vs. 20 
EPC/DO-Lipo. The experiment was performed 5 times independently, and the sum of the data of 21 
each experiment is shown. 22 
 23 
Figure 6. Effect of treatment with leukocyte-mimetic liposomes on the actin cytoskeleton in 24 
TNF-α-treated HUVECs. 25 




TNF-α (10 ng/mL in EGM-2 medium) for 16 h at 37ºC. The cells were then treated with DiI-labeled 1 
EPC/DO-Lipo or leukocyte-mimetic liposomes (LM-EPC/DO-Lipo (ATRA (-) or ATRA (+)) for 3 h 2 
at 37ºC. The cells were then fixed with 4% PFA, permeabilized with PBS containing 0.1% 3 
TritonX-100, and incubated with 1% BSA in PBS, followed by staining with Alexa Fluor 4 
488-conjugated phalloidin solution. Finally, the nuclei of the cells were stained with DAPI, and the 5 
fluorescence was observed using a confocal laser scanning microscope. Images were obtained from 6 
untreated (TNF-α (-)) HUVECs (A), or TNF-α-treated HUVECs treated with plain liposomes (B), 7 
LM-EPC/DO-Lipo (ATRA (-)) (C), or LM-EPC/DO-Lipo (ATRA (+)) (D). Blue, green, and red 8 
colors represent the individual fluorescence of DAPI (nuclei), Alexa Fluor 488 (F-actin) and DiI 9 
(liposome), respectively. Scale bars = 20 μm. The experiment was independently performed 4 times, 10 
all of which showed similar profiles. 11 
 12 
Figure 7. Influence of leukocyte-mimetic liposomes on the intercellular adhesion protein 13 
VE-cadherin in inflamed endothelial cells. 14 
 (A-D) TNF-α-treated HUVECs were treated with each liposome according to the same 15 
procedure described in the legend of Fig. 6. After removing the liposomal samples, the cells were 16 
fixed with 4% PFA and permeabilized with PBS containing 1% BSA and 0.1% Triton X-100. 17 
Thereafter, the cells were incubated with anti-VE cadherin antibody for 1 h at 37ºC, followed by 18 
incubation with Alexa Fluor 488-conjugated secondary antibody for 1 h at 37ºC. After staining the 19 
nuclei with DAPI, fluorescence images were obtained from untreated HUVECs (A), and 20 
TNF-α-treated HUVECs treated with the indicated liposomes (B-D) by confocal laser scanning 21 
microscopy. Blue and green colors show the fluorescence of DAPI (nuclei) and Alexa Fluor 488 22 
(VE-cadherin), respectively. Scale bar = 20 μm. The experiments were performed 5 times 23 
independently. (E) The relative fluorescence intensity of VE-cadherin positive area between cell 24 
borders to that in control was calculated from over 8 or more images per each group of HUVECs for 25 




analyzed by ANOVA with Tukey post-hoc test. Significant differences; ### P<0.001 vs. Control 1 
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